10/03/2008
ReGen Appoints Golgi Pharmaceuticals Ltd of Cyprus as first European-based Distributor for ColostrininTM.
ReGen Therapeutics Plc (‘ReGen’or the ‘Company’) is pleased to announce that it has today signed the first European distribution agreement for its nutritional supplement ColostrininTM with Golgi Pharmaceuticals Ltd of Cyprus.* This deal is conditional on Golgi being able to secure importation approval for the product from the Cypriot authorities, which it has now applied for. To date ColostrininTM is marketed in the US and Australian markets under the brand name CogniSureTM as a nutritional supplement to ‘support healthy brain aging and cognition in humans’**
Commenting on the first agreement signed in the European Union Percy Lomax, Chairman and Chief Executive Officer of ReGen said :
‘Cyprus is a relatively small market in its own right but it is a member of the European Union which, with the US and Japan, is one of the three key target areas for ColostrininTM. This launch is into the professional and retail channel and this allows distribution in all health food stores and pharmacies’.
* Golgi Pharmaceuticals Ltd is a distributor of pharmaceuticals and nutraceuticals in the Republic of Cyprus. (email address of Golgi Pharmaceuticals Ltd – golgipha@cytanet.com.cy)
**ColostrininTM for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.Metagenics.com). Discussions are ongoing with potential distributors in other regions of the world.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396